Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_assertion type Assertion NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_head.
- NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_assertion description "[In a phase 2 study we aimed to assess the efficacy and safety of grazoprevir (MK-5172; HCV NS3/4A protease inhibitor) and two doses of elbasvir (MK-8742; HCV NS5A inhibitor) in patients with HCV mono-infection and HIV/HCV co-infection.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_provenance.
- NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_assertion evidence source_evidence_literature NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_provenance.
- NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_assertion SIO_000772 25467560 NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_provenance.
- NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_assertion wasDerivedFrom befree-2016 NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_provenance.
- NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_assertion wasGeneratedBy ECO_0000203 NP1244173.RAnTPV3uAe7DImUn9goaw8i0kW5d2z__H_5hsulKCfexg130_provenance.